Genomics England has named the four companies it wants to work with on the interpretation of the first 8,000 genomes from its massive sequencing effort. The list of successful bidders is lacking some big-name applicants, with Illumina and Qiagen among the companies to miss out.
A team at the University of California, San Diego (UCSD), has found biomarkers for ovarian tumors by mining two National Institutes of Health-sponsored databases. The bioinformatics-enabled research program has raised expectations that earlier diagnoses of ovarian cancer can be made, an advance that could improve outcomes in a tough therapeutic indication.
Genomics England has run into teething problems in the first few months of its massive genome sequencing initiative. About half of tumor samples sequenced to date have yielded substandard data, a shortcoming Genomics England is trying to overcome by trialing new processes and working with hospitals to incorporate the practices into their day-to-day tasks.
Israel has become the latest country to disclose plans to create a population-scale database of linked genetic and clinical records. The current plan is reminiscent of the United Kingdom's 100,000 Genomes Project, with Israel considering working with tech firms to create a database of patients with rare genetic diseases.
J. Craig Venter's Human Longevity Inc. (HLI) has struck a deal with the Cleveland Clinic to access blood samples. The initial focus of the deal is on the sequencing and analysis of samples in Cleveland Clinic's GeneBank.
GenomeDx Biosciences is making its pool of clinically annotated data on the genomics of urological cancers available to Sidney Kimmel Cancer Center.
AstraZeneca is digging through the genomes of 80,000 people in search of genes linked to cardiovascular diseases and diabetes. The project is a collaboration with the Montreal Heart Institute, which will genotype 80,000 samples from AstraZeneca's biobank of blood and tissue samples.
Agilent Technologies has struck a deal to acquire Cartagenia. The buyout will give Agilent software to interpret clinical genomics data, an asset it plans to offer to its molecular oncology customers.
Edico Genome has hooked up with Intel in an attempt to shave more minutes off the time it takes to analyze a whole genome. The partnership brings together Edico's NGS analysis hardware and the Intel Xeon microprocessors that reside in many servers used in genomics.
Quest Diagnostics has teamed up with French human health research institute Inserm to pool and share BRCA1 and BRCA2 genetic data. LabCorp has signed up as the first participant in the program, giving it a sizable reach from day one.